Morgan Stanley Maintains Overweight on ShockWave Medical, Lowers Price Target to $284
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Patrick Wood has maintained an Overweight rating on ShockWave Medical (NASDAQ:SWAV) but lowered the price target from $313 to $284.
November 07, 2023 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Morgan Stanley has maintained an Overweight rating on ShockWave Medical but lowered the price target from $313 to $284.
The news is directly related to ShockWave Medical (SWAV). While the Overweight rating is maintained, indicating a positive outlook, the lowering of the price target could create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100